As one of the world’s top — and certainly best paid — antibody drug developers, Regeneron’s George Yancopoulos tends to attract a considerable amount of attention when he gets excited by one of his clinical projects. And today you’ll find him eagerly touting a bispecific therapy that the R&D chief has sky-high hopes for.
Evidently with good reason.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.Free Subscription